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respectively. Favourable prognostic factors in univariate and 
multivariate analysis were early stage, tumour size < 4 cm (after 
adjusting for the residual disease after radiation), no pelvic 
lymph node involvement and one week gap between EBRT and 
HDR brachytherapy in three-year DFS (p = 0.001, p = 0.012, p = 
0.005, p = 0.005 respectively). The three-year OS rate was 85.7%, 
76.4%, 42%, and 33.3% for Stages I, II, III, and IVA, respectively. 
Favourable prognostic factors in univariate and multivariate 
analysis were early stage, tumour size < 4 cm, no pelvic lymph 
node involvement, one week gap between EBRT and HDR 
brachytherapy and no distant metastasis (during the follow up) 
in three-year OS (p = 0.001, p = 0.002, p = 0.002, p = 0.002, p = 
0.001 respectively). 
Conclusions: HDR brachytherapy with Co-60 remote after 
loading system was successful and it showed HDR brachytherapy 
in treating patients with carcinoma of cervix was effective after 
EBRT with acceptable rectal and bladder complications. 
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INTRAOPERATIVE FACTORS ASSOCIATED WITH IODINE-125 
PLACEMENT ACCURACY IN PROSTATE BRACHYTHERAPY 
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Ronald Sloboda, Mahdi Tavakoli, John Amanie, Don Yee, Albert 
Murtha, Nawaid Usmani 
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Purpose: The quality of prostate brachytherapy implant depends 
on accurate placement of seeds in their intended locations. This 
study will investigate intraoperative factors that potentially 
contribute to seed placement inaccuracy in prostate 
brachytherapy. 
Methods and Materials: Intraoperative video images of the 
brachytherapist’s hands motion and needle insertions during the 
implant procedure were acquired for analysis. Using video 
analysis software, maximum and average insertion velocities 
were measured. Number of needle insertion attempts and the 
use of brachytherapist’s other hand to manipulate the lateral 
needle movements were also recorded. Magnitude of seed 
displacements from their target location were measured in 
ultrasound images acquired following completion of each implant 
using VariSeed treatment planning software. 
Results: Fifteen patients agreed to undergo this study. 1619 
iodine-125 seeds were inserted using 357 needles. 1197 seeds 
were confidently identified in the ultrasound images and 
included in the analysis. Mean overall displacement was 0.49 cm 
(0 to 2.1 cm, 95% CI = 0.48-0.52). Six hundred and fourteen seeds 
were delivered with a single pass and 583 seeds were delivered 
with > 1 passes (range 1 to 6). Mean maximum velocity was 12.17 
cms-1 (range 4 to 28 cms-1) and mean average velocity was 4.77 
cms-1 (range 0.4 to 17.4 cms-1). Seven hundred and forty-seven 
seeds were delivered with manipulation of the needle by the 
brachytherapist’s other hand. Generalized linear model (GLM) 
was used to determine the factors contributing to seed 
displacement and found that maximum insertion velocities < 12 
ms-1 was associated with a decrease in seed displacements by 
0.049cm compared to maximum speed of > 12 cms-1 (95%CI:-
0.09;-0.01, p = 0.0121). Other evaluated factors did not show any 
no statistically significant correlation with seed displacement: 
average speed (95%CI:-0.05;0.02, p = 0.4947), lateral 
manipulation of needle (95%CI:-0.04;0.04, p = 0.9264) and 
number of needle passes (95%CI:-0.02;0.01, p = 0.8907). 
Conclusions: This study identified that needles inserted with 
lower maximum velocities were associated with less seed 
displacement. Lateral manipulation of needle, number of passes 
and average speed did not show statistically significant 
correlation with the magnitude of seed displacement. 
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PAIN AND OPIOID USE IN GYNECOLOGICAL CANCER PATIENTS 
TREATED WITH INTERSTITIAL BRACHYTHERAPY  
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Purpose: Interstitial brachytherapy (ISBT) implantation has 
advantages over standard intracavitary techniques in locally-
advanced gynecological malignancies. The insertion of implanted 
catheters directly into tumour tissue enables higher radiation 
dose conformality and normal tissue sparing. Nevertheless, this 
procedure can be associated with pain and discomfort because 
of its invasiveness. The goal of this study is to assess pain and 
opioid use by patients implanted with a perineal ISBT applicator 
for treatment with brachytherapy. 
Methods and Materials:  Thirty-nine patients treated with high-
dose rate ISBT using a perineal template from September 2014 
to January 2016 were included in a prospective registry trial. 
Median age was 65 (range 23-88) and the cohort included 13 
cervical cancers patients, 11 primary vaginal cancers, 11 
recurrent endometrial cancers, one vulvar cancer and three 
palliative treatments. Patient characteristics (age, obesity, 
diabetes, use of anti-depressants/anxiolytics) and technical ISBT 
implantation data (number of needles, depth of implantation and 
pelvic organ intrusion) were collected. Quantity of opioid use 
(morphine-oral-equivalent-dose (MoED) per day) and maximum 
pain scores (0-10) at rest or with movement were evaluated. 
Paired t-test was used for opioid comparison between first and 
second implantations. Regression linear analysis was used to 
identify independent predictors of opioid use. 
Results: The majority of patients (34) were initially treated with 
a course of external beam radiation therapy with a median dose 
of 45 Gy to the pelvis. Twenty-two patients had a single ISBT 
implantation while 17 had a second implantation, one week 
later. The median number of needles used for each implant was 
17 (8-26) and a median of three (2-5) fractions of ISBT treatments 
were delivered. Mean MOeD use per day was statistically higher 
for the second (55 mg versus 81 mg) procedure as compared to 
the first insertion (p < 0.05). Maximum pain score at rest or 
movement was also higher after the second implantation (5/5 
versus 7/6). Age (continuous variable) and numbers of implanted 
catheter needles (dichotomized by median- 17 or less versus > 
17) were found to be significant predictors of opioid use for the
first procedure. Depth of catheter insertion and pelvic organ 
intrusion were not correlated to opioid use or pain score. 
Conclusions: Interstitial brachytherapy patients require 
adequate analgesia with opioids after applicator insertion and 
inpatient stay. The second ISBT implantation is associated with 
greater opioid consumption and higher median pain scores 
(moderate versus moderate to severe). The number of implanted 
needles correlated with increase in opioid use, whereas age had 
an inverse correlation. 
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MODELS OF CARE FOR CERVICAL CANCER BRACHYTHERAPY IN 
ONTARIO  
Kitty Chan1, Quinn Benwell2, Ken Schneider3, Michelle Ang4, 
David D'Souza2, Michael Milosevic1, Lisa Barbera5 
1Princess Margaret Cancer Centre, Toronto, ON 
2London Regional Cancer Program, London, ON 
3Windsor Regional Cancer Centre, Windsor, ON 
4Cancer Care Ontario, Toronto, ON 
5Odette Cancer Centre, Toronto, ON 
Purpose: Magnetic resonance (MR) is considered the gold-
standard imaging modality to guide cervical cancer 
brachytherapy (BT), however introducing this modality into a BT 
process can be challenging. The Models of Care Working Group 
within Cancer Care Ontario’s Gynaecological Community of 
Practice (GYN CoP) of the Radiation Treatment Program focused 
on developing strategies for Ontario patients to access this 
technology and expertise. The aim of this study is to identify 
current models of care for cervical cancer brachytherapy (ccBT) 
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in Ontario (ONT) and to develop recommendations to ensure all 
patients to have equitable access to MR-guided brachytherapy 
(MRgBT) for cervical cancer. 
Methods: A qualitative phone interview was designed by the GYN 
CoP working group to survey the current state of ccBT in the 
province. Questions were developed to inquire about the current 
use of image-guided ccBT and the associated referral processes, 
the usage of MR imaging in ccBT and the current use of image-
guided interstitial GYN BT. All ONT cancer centres offering 
radiation treatments to GYN cancers were included. Two group 
members conducted and audio recorded the telephone 
interviews from May to November 2015 and analyzed all 
recordings and summarized the data. 
Results: Thirteen (n = 13) ONT cancer centres were interviewed. 
Of these, three centres do not offer ccBT, five centres offer CT-
guided ccBT, four centres offer a combination of CT-MR-guided 
ccBT and one centre offers strictly MR-guided ccBT. The three 
centres that do not offer ccBT have established referral 
processes with three tertiary cancer centres in ONT respectively. 
However, there is no standardized referral process, referral 
timing, or method of communication. Other practices vary 
throughout the centres. Three of 13 centres suggested 
developing a file portal to standardize and facilitate the sharing 
of external beam and BT plans, distributions and images. All CT-
guided ccBT centres except one have plans to develop MRgBT. 
The tertiary centres mentioned above are also the only centres 
that offer interstitial GYN BT. They are located in the 
southwestern part of the province. Of these, one centre offers 
CT-guided and two centres offer MR-guided interstitial GYN BT. 
There is currently no standardized guideline to identify patient 
candidates for interstitial GYN BT. 
Conclusions: This study demonstrated that models of shared 
care exist and are functioning in ONT. While referral processes 
are functioning well, some areas represent opportunities for 
improvement. Future work is needed by the GYN CoP to improve 
referral processes and to develop consensus on indications for 
interstitial brachytherapy. This will ensure all patients in ONT 
have access to this high quality brachytherapy.  
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Purpose: To determine the optimal patient positioning and most 
reliable measurements for placement of skin marks during the 
mark-up procedure prior to PBSI brachytherapy for breast 
cancer. 
Methods and Materials: A retrospective chart review was 
conducted among patients who had imaging assessments to 
determine eligibility for PBSI following breast conserving surgery 
for Stage 0-1 breast cancer. Eligible patients had received CT 
imaging to determine the size and location of the seroma. 
Patients had treatment plans created, with a CT reference 
marker placed on the medial aspect of the nipple and tattoos 
consistent with standard institutional practice for external beam 
radiation treatments (EBRT). For patients receiving PBSI, skin 
markings were placed on the patient’s breast to map the 
implant, on the morning of the procedure. The interval from 
planning CT to implant date was two to four weeks. For this 
study, mark-up and delivery data were documented and 
deviations between planning CT and implant data for PBSI, were 
reviewed to determine the most reliable measurements for 
patient positioning and mark-up. 
Results: Among 40 patients initially assessed for PBSI, 27 
proceeded to implant and 13 ineligible patients (seroma too 
large or close to skin) had EBRT. The EBRT set-up tattoos used in 
PBSI were observed to have significant deviations from the 
planning CT, due to the variation in arm placement between the 
two treatment modalities. Measurements to determine the 
fiducial entry point referencing the nipple marker were 
determined to have a mean deviation of < 1 mm while those from 
the table top to the tattoo was 6mm and from the table top to 
the fiducial was 8 mm. 
Conclusions: Two-thirds of patients assessed were eligible and 
received PBSI. Temporary markings should be used at the time 
of assessment CT with permanent tattoos applied only after of 
the treatment modality is finalized. Measurements from the 
table are less reliable than those referencing the nipple marker. 
Set-up variations on the table top, possibly due to loose tissue 
and patient rotation, make measurements referencing patient’s 
markings the most reliable. 
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Purpose: To propose an effective training program for radiation 
therapy teams starting to implement PBSI brachytherapy for 
early stage breast cancer. 
Methods and Materials: A PBSI program requires a 
multidisciplinary team including physicians, physicists, 
dosimetrists, radiation therapists, operating room nurses, 
anesthetists, machinists and administrative personnel. A PBSI 
program was launched in 2013. Multiple CT and ultrasound 
compatible gel phantoms that mimicked breast tissue with 
embedded seromas, were designed and constructed. Physicians 
practiced ultrasound guided needle placement into numerous 
phantoms, with seromas in various locations, to simulate actual 
patient implants. Post-implant CT scans of phantoms were used 
to assess implant accuracy. Observations recorded prospectively 
during the practice implants on phantoms and mock PBSI 
deliveries were used to guide process development, improve 
quality and refine training, education, and experience. 
Results: Based on our development research, results, and 
experience, we suggest that a centre starting a PBSI program 
should have an onsite training course that includes the following 
modules: 
1) PBSI theory: including background, patient eligibility, patient 
assessments and suitability, process from assessment to 
treatment and patient care; 
2) Treatment planning session: including dosimetric goals and 
objectives, hands on clinical case examples with comparison to 
benchmark plans and guided physician evaluation; 
3) Participant observation of a PBSI operating room procedure; 
4) Active involvement of the participants in practice sessions 
with phantoms and realistic operating room scenarios; 
5) Wrap up session: opportunity to share experiences and 
problem solve. Group discussion on how to translate their 
learning to their own practice. Feedback from participants on 
this training program and areas for improvement; and 
6) Follow up: remote pre-plan consults and/or reviews as well as 
post-plan analyses for several cases. 
Conclusions: Effective training with hands on experience 
followed by support after centre implementation will improve 
the learning curve, increase confidence, and assist radiation 
therapy teams to set up a breast brachytherapy program in their 
department. 
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Purpose: The risk of tumour progression and recurrence is an 
important consideration when treating prostate cancer. Risk 
assessment includes clinical staging through physical 
